Showing 38,661 - 38,680 results of 103,778 for search '(( e point decrease ) OR ( 5 ((wt decrease) OR (((we decrease) OR (a decrease)))) ))', query time: 1.97s Refine Results
  1. 38661
  2. 38662
  3. 38663
  4. 38664
  5. 38665
  6. 38666
  7. 38667

    EphA3 ectodomain stimulates nasal RGC axon growth in vitro. by Ana Laura Ortalli (159899)

    Published 2012
    “…Temporal RGCs did not present any significant change in axon growth on EphA3-Fc between 0.5 and 4 nM and presented a significant decrease at 8 nM (ANOVA and Tukey postest, 3 independent experiments, n: 20 longer axons for explant, 3 explants for condition). …”
  8. 38668

    ATRA treatment induces expression of S100 and inhibits PMP22 expression. by Susan Fischer-Huchzermeyer (4588522)

    Published 2017
    “…<p>Flow cytometry analysis (FACS) of S100 and PMP22 protein expression in ATRA treated MPNST cells on day 7 of treatment (5μM). Bars indicate increase or decrease of fluorescence intensity (%) compared to untreated controls (100%). …”
  9. 38669
  10. 38670
  11. 38671
  12. 38672
  13. 38673
  14. 38674
  15. 38675
  16. 38676
  17. 38677

    Supplementary Material for: Group- and Home-Based Cognitive Intervention for Patients with Mild Cognitive Impairment: A Randomized Controlled Trial by Jeong J.H. (3199218)

    Published 2016
    “…<b><i>Results:</i></b> In comparison to the controls (a 0.8-point decrease), the subjects receiving GCI (a 2.3-point decrease, p = 0.01) or HCI (a 2.5-point decrease, p = 0.02) showed significant improvements in the modified ADAS-Cog at PI, respectively. …”
  18. 38678
  19. 38679

    Diabetes, Drug Treatment and Mortality in COVID-19: A Multinational Retrospective Cohort Study by Jennifer E. Nyland (11412878)

    Published 2021
    “…Glucose-regulating medications such as glucagon-like peptide-1 receptor (GLP-1R) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and pioglitazone are known to have anti-inflammatory effects that may improve outcomes in patients with SARS-CoV-2 infection. In a multinational retrospective cohort study, we used the TriNetX COVID-19 Research Network of 56 large healthcare organizations to examine these medications in relation to the incidence of hospital admissions, respiratory complications, and mortality within 28 days following a COVID-19 diagnosis. …”
  20. 38680